TREATMENT SET TS346889 injection, solution TREATMENT SET TS346962 injection, solution TREATMENT SET TS347116 injection, soluti

Страна: США

мова: англійська

Джерело: NLM (National Library of Medicine)

Активний інгредієнт:

PLANTAGO LANCEOLATA POLLEN (UNII: DO87T1U2CI) (PLANTAGO LANCEOLATA POLLEN - UNII:DO87T1U2CI), URTICA DIOICA POLLEN (UNII: DNB59M1NVU) (URTICA DIOICA POLLEN - UNII:DNB59M1NVU), AMARANTHUS RETROFLEXUS POLLEN (UNII: 73B14PX5FW) (AMARANTHUS RETROFLEXUS POLLEN - UNII:73B14PX5FW), AMBROSIA ARTEMISIIFOLIA POLLEN (UNII: K20Y81ACO3) (AMBROSIA ARTEMISIIFOLIA POLLEN - UNII:K20Y81ACO3), CYNODON DACTYLON POLLEN (UNII: 175F461W10) (CYNODON DACTYLON POLLEN - UNII:175F461W10), FESTUCA PRATENSIS POLLEN (UNII: A0WFQ8P6N

Доступна з:

Antigen Laboratories, Inc.

ІПН (Міжнародна Ім'я):

PLANTAGO LANCEOLATA POLLEN

Склад:

PLANTAGO LANCEOLATA POLLEN 0.002 g in 1 mL

Адміністрація маршрут:

SUBCUTANEOUS

Терапевтичні свідчення:

When the natural exposure to elevated aeroallergens produces symptoms as described under Clinical Pharmacology, specific diagnosis and therapeutic procedures are indicated. Clearly, important clues to the cause of a person's allergic condition can be gleaned from a thorough history and careful physical examination. Diagnostic tests - in vitro or in vivo - serve only to confirm the physician's suspicions or to improve investigative skills. Specific diagnosis is especially indicated when the patient's symptoms are not controlled by medication. When immunotherapy is contemplated demonstration of sensitivity to a specific allergenic extract is necessary. An orderly approach to the use of diagnostic tests usually begins with direct skin testing. 5,6,11 THIS PRODUCT IS NOT INTENDED FOR TREATMENT OF PATIENTS WHO DO NOT MANIFEST IMMEDIATE HYPERSENSITIVITY REACTIONS TO THE ALLERGENIC EXTRACT FOLLOWING SKIN TESTING. There are no absolute contraindications; however, extreme caution is necessary when using diagnostic ski

Огляд продуктів:

Individual treatment sets as prescribed by the physician. The allergenic extract contains a variable number of individual doses depending on the patient's sensitivity and maximum tolerated maintenance treatment dose.

Статус Авторизація:

Biologic Licensing Application

Характеристики продукта

TREATMENT SET TS346889 - TREATMENT SET TS346889 INJECTION, SOLUTION
TREATMENT SET TS346962 - TREATMENT SET TS346962 INJECTION, SOLUTION
TREATMENT SET TS347116 - TREATMENT SET TS347116 INJECTION, SOLUTION
TREATMENT SET TS346963 - TREATMENT SET TS346963 INJECTION, SOLUTION
TREATMENT SET TS346964 - TREATMENT SET TS346964 INJECTION, SOLUTION
TREATMENT SET TS347115 - TREATMENT SET TS347115 INJECTION, SOLUTION
TREATMENT SET TS347226 - TREATMENT SET TS347226 INJECTION, SOLUTION
TREATMENT SET TS347227 - TREATMENT SET TS347227 INJECTION, SOLUTION
TREATMENT SET TS347249 - TREATMENT SET TS347249 INJECTION, SOLUTION
TREATMENT SET TS347250 - TREATMENT SET TS347250 INJECTION, SOLUTION
TREATMENT SET TS347335 - TREATMENT SET TS347335 INJECTION, SOLUTION
TREATMENT SET TS347336 - TREATMENT SET TS347336 INJECTION, SOLUTION
TREATMENT SET TS347337 - TREATMENT SET TS347337 INJECTION, SOLUTION
TREATMENT SET TS347338 - TREATMENT SET TS347338 INJECTION, SOLUTION
TREATMENT SET TS347483 - TREATMENT SET TS347483 INJECTION, SOLUTION
TREATMENT SET TS347484 - TREATMENT SET TS347484 INJECTION, SOLUTION
TREATMENT SET TS347536 - TREATMENT SET TS347536 INJECTION, SOLUTION
TREATMENT SET TS347537 - TREATMENT SET TS347537 INJECTION, SOLUTION
TREATMENT SET TS347627 - TREATMENT SET TS347627 INJECTION, SOLUTION
TREATMENT SET TS347628 - TREATMENT SET TS347628 INJECTION, SOLUTION
ANTIGEN LABORATORIES, INC.
----------
ALLERGENIC EXTRACTS
INDIVIDUAL TREATMENT VIAL
WARNINGS
INDIVIDUAL ALLERGENIC EXTRACT TREATMENT VIAL IS INTENDED FOR USE BY
PHYSICIANS WHO ARE
EXPERIENCED IN THE ADMINISTRATION OF ALLERGENIC EXTRACTS FOR
IMMUNOTHERAPY AND THE
EMERGENCY CARE OF ANAPHYLAXIS, OR FOR USE UNDER THE GUIDANCE OF AN
ALLERGY SPECIALIST.
INDIVIDUAL ALLERGENIC EXTRACT TREATMENT VIALS ARE NOT DIRECTLY
INTERCHANGEABLE WITH OTHER
ALLERGENIC EXTRACTS. THE INITIAL DOSE MUST BE BASED ON SKIN TESTING AS
DESCRIBED IN THE
DOSAGE AND ADMINISTRATION SECTION OF THIS INSERT. PATIENTS BEING
SWITCHED FROM OTHER TYPES
OF EXTRACT TO INDIVIDUAL TREATMENT VIALS SHOULD BE STARTED AS THOUGH